About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Cut-and-Paste Your Way to Publication | Main | You May Not Be Interested In It - But It's Interested In You »

September 10, 2010

Sanofi-Aventis: It's $69/Share, And That's Where It Stays

Email This Entry

Posted by Derek

Despite a number of reports yesterday and over night that Sanofi-Aventis had raised their offer for Genzyme shares, they're saying now that they've done no such thing. It's the same $69/share offer that was made public, and they're apparently lobbying the larger Genzyme shareholders to make them see the wisdom of the offer.

So if it's not going to be a bidding war, then most of the interesting stuff is going to be taking place behind the scenes. Will some of the big investors decide that S-A's offer is better than trusting Genzyme's management? Or will hang with the current team? Or (most likely, in my opinion) will they make no commitments to anyone while they wait to see if the offer gets higher (after more pressure is applied)?

Comments (7) + TrackBacks (0) | Category: Business and Markets


1. Modeler on September 10, 2010 8:46 AM writes...

More interestingly, will Genzyme get tired of SA's heckling and itself solicit higher quotes from other big pharma companies?

Permalink to Comment

2. watcer on September 10, 2010 12:36 PM writes...

It seems there's no incentive in the market-place for S-A with no competing offers. Genzyme has yet to show they can dig themselves out of their manfacturing problems, so their self-valuation must be considered on the optimistic, high side. With today's stock market and the general stagnation of drug stock prices, appeal to general stockholders of Genzyme seems to be a good wager for S-A's price proposal. My bet is that they will go for it.

Permalink to Comment

3. Hap on September 10, 2010 12:47 PM writes...

If it were such a good deal, S-A wouldn't have to twist arms to get people to sell to them - the uncertainties in Genzyme are pretty well known, and given the state of the market, people might want to get their money while they can. I would figure, thus, that S-A is twisting arms because the current deal is good for them but not obviously good for stockholders. There may also be a lot of people in Genzyme for the long haul for whom a merger will likely do them no good at all (considering the past history of mergers in pharma) who may not want to sell unless they're sure everyone else is selling (and they will need to get out while they can).

Permalink to Comment

4. Anon on September 10, 2010 1:10 PM writes...

".....pigs get slaughtered....."

Permalink to Comment

6. horrible on September 10, 2010 3:34 PM writes...

Layoffs at Genz today

Permalink to Comment

7. Anon-2 on September 11, 2010 8:45 AM writes...

Genz can't buy enough time to fix their manufacturing problems while surviving on their own at current size & make-up. It's a tragedy to many who are involved, but this is an exmple of what happens with a "one trick pony" when the star goes lame. A few months more and $69 / share will likely good very good to them when no one else shows interest.

Permalink to Comment


Remember Me?


Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry